Human-derived bacteria that induce proliferation or accumulation of regulatory T cells

Patent metadata

Field	Value
Publication number	US-10835559-B2
Application number	US-201816170344-A
Country	US
Kind code	B2
Filing date	Oct 25, 2018
Priority date	Dec 1, 2011
Publication date	Nov 17, 2020
Grant date	Nov 17, 2020

Abstract

Species of human-derived bacteria belonging to the Clostridia class have been shown to induce accumulation of regulatory T cells (Treg cells) in the colon and suppress immune functions. Pharmaceutical compositions containing these bacteria can be used to prevent and treat immune-mediated diseases such as autoimmune diseases.

First claim

What is claimed is:

1. A pharmaceutical composition comprising a purified bacterial mixture comprising three or more bacterial strains selected from the group consisting of
Clostridium saccharogumia or Clostridium ramosum JCM1298,
Flavonifractor plautii or Pseudoflavinofractor capillolus ATCC 29799,
Clostridium hathewayi or Clostridium saccharolyticum WM1,
Blautia coccoides or Lachnospiraceae bacterium 6_1_63FAA,
Clostridium sp. or Clostridium bolteae ATCC BAA-613,
cf. Clostridium sp. MLGO55 or Erysipelotrichaceae bacterium 2_2_44A
Clostridium indolis or Anaerostipes caccae DSM 14662,
Anaerotruncus colihominis or Anaerotruncus colihominis DSM 17241,
Ruminococcus sp. ID8 or Lachnospiraceae bacterium 2_1_46FAA,
Clostridium lavalense or Clostridium asparagiforme DSM 15981,
Clostridium symbiosum or Clostridium symbiosum WAL-14163,
Clostridium ramosum,
Eubacterium contortum or Clostridium sp. D5,
Clostridium scindens or Lachnospiraceae bacterium 5_1_57FAA,
Lachnospiraceae bacterium A4 or Lachnospiraceae bacterium 3_1_57FAA_CT1,
Clostridium sp. 316002/008 or Clostridiales bacterium 1_7_47FAA, and
Lachnospiraceae bacterium A4 or Lachnospiraceae bacterium 3_1_57FAA_CT1; and one or more enteric polymers.

2. The composition of claim 1 , wherein the purified bacterial mixture comprises at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16 or at least 17 bacterial strains.

3. The pharmaceutical composition of claim 1 , wherein the bacterial strains are human-derived bacteria.

4. The pharmaceutical composition of claim 1 , wherein the bacterial strains are human commensal bacteria.

5. The pharmaceutical composition of claim 1 , wherein one or more of the bacterial strains are in spore-form.

6. The pharmaceutical composition of claim 1 , further comprising a pharmaceutically acceptable excipient.

7. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition is formulated for oral administration.

8. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition is formulated for delivery to the intestine or colon.

9. A pharmaceutical composition comprising a purified bacterial mixture consisting of the following 17 bacterial strains:
Clostridium saccharogumia or Clostridium ramosum JCM1298,
Flavonifractor plautii or Pseudoflavinofractor capillolus ATCC 29799,
Clostridium hathewayi or Clostridium saccharolyticum WM1,
Blautia coccoides or Lachnospiraceae bacterium 6_1_63FAA,
Clostridium sp. or Clostridium bolteae ATCC BAA-613,
cf. Clostridium sp. MLGO55 or Erysipelotrichaceae bacterium 2_2_44A,
Clostridium indolis or Anaerostipes caccae DSM 14662,
Anaerotruncus colihominis or Anaerotruncus colihominis DSM 17241,
Ruminococcus sp. ID8 or Lachnospiraceae bacterium 2_1_46FAA,
Clostridium lavalense or Clostridium asparagiforme DSM 15981,
Clostridium symbiosum or Clostridium symbiosum WAL-14163,
Clostridium ramosum,
Eubacterium contortum or Clostridium sp. D5,
Clostridium scindens or Lachnospiraceae bacterium 5_1_57FAA,
Lachnospiraceae bacterium A4 or Lachnospiraceae bacterium 3_1_57FAA_CT1,
Clostridium sp. 316002/008 or Clostridiales bacterium 1_7_47FAA, and
Lachnospiraceae bacterium A4 or Lachnospiraceae bacterium 3_1_57FAA_CT1; and one or more enteric polymers.

10. The pharmaceutical composition of claim 9 , wherein the bacterial strains are human-derived bacteria.

11. The pharmaceutical composition of claim 9 , wherein the bacterial strains are human commensal bacteria.

12. The pharmaceutical composition of claim 9 , wherein one or more of the bacterial strains are in spore-form.

13. The pharmaceutical composition of claim 9 , further comprising a pharmaceutically acceptable excipient.

14. The pharmaceutical composition of claim 9 , wherein the pharmaceutical composition is formulated for oral administration.

15. The pharmaceutical composition of claim 9 , wherein the pharmaceutical composition is formulated for delivery to the intestine or colon.

Assignees

• Univ Tokyo
• School Corporation Azabu Veterinary Medicine Educational Inst

Inventors

• Honda Kenya
• Atarashi Koji
• Tanoue Takeshi
• Hattori Masahira
• Morita Hidetoshi

Classifications

• C12R2001/145

  Clostridium · CPC title

• C12N1/205

  Bacterial isolates · CPC title

• A61K9/0053

  Mouth and digestive tract, i.e. intraoral and peroral administration · CPC title

• A61K35/745

  Bifidobacteria · CPC title

• A61K35/74 Primary

  Bacteria (therapeutic use of a bacterial protein A61K38/00) · CPC title